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Varicella-zoster virus (VZV) usually causes localized zoster in adults. However, in immunocompromised patients,
it can cause systemic infection accompanied by complications such as pneumonia, encephalitis, and hepatitis.
Although most of critically ill patients in intensive care unit (ICU) are immunologically compromised, they are
usually not considered to be at risk for systemic VZV infection.
We report two cases of systemic VZV infection occurring in critically ill patients in an ICU. One patient was a
69-year-old man with Streptococcus pneumoniae-induced purpurafulminans, and the other was a 75-year-old woman
with severe acute pancreatitis. During the clinical course in the ICU, characteristic vesicles with umbilical fossa appeared
diffusely and bilaterally on their face, trunk, and extremities. VZV-specific IgG levels were confirmed to be elevated
compared to that of the pre-onset, and a diagnosis of recurrent VZV infection was made in both patients. The patients
were treated at the same ICU but did not coincide with each other; therefore a cross-infection was unlikely. They were
treated with intravenous acyclovir, but the latter patient eventually died of respiratory failure.
VZV infection can cause a number of serious complications, and can lead to death in some patients. Early detection
and proper treatment are needed to prevent the infection from spreading out and save the patients. It might be
necessary to consider antiviral prophylaxis against VZV infection for a part of critically ill patients in ICU, although the
effectiveness of this approach is yet to be established.
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Varicella-zoster virusBackground
Varicella-zoster virus (VZV) has the potential to cause
life-threatening infection in adults, especially in those who
are immunocompromised. In addition to specific humoral
immunity, cellular-mediated immunity is involved in pro-
tection against VZV infection [1-3]. Pneumonia, encephal-
itis, hepatitis, and disseminated intravascular coagulopathy
(DIC) are well-known complications of systemic VZV
infection, and the overall mortality rate has been reported
to be high in such cases (approximately 30% among renal
transplant patients) [4]. Previous studies have reported
that transplant recipients, human immunodeficiency virus
(HIV)-infected patients, and patients undergoing treat-
ment with tumor necrosis factor-α inhibitors are at an
increased risk of developing severe VZV infection [5-7].* Correspondence: e_dai_for_all@hotmail.com
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tend to be immunologically weak [8-12] and they are
considered to be at a high risk for various opportunistic
infections. However, systemic VZV infection has not
been considered as such an opportunistic infection in
ICU patients and its clinical picture has yet to be well
assessed to date. We present 2 cases of systemic VZV
infection occurring in critically ill patients in the ICU.Case presentation
Case 1
A 69-year-old man presenting with chills, rigor, stomach-
ache, and vomiting was admitted to a hospital in a state of
shock. He had undergone bone marrow transplantation
and chemotherapy for multiple myeloma 4 years ago and
had been administered prednisolone (PSL; 5 mg/day at
that time) since then. Physical examination revealed sys-
temic purpuric rash and laboratory tests showed renal
impairment, liver disorder, a highly inflammatory state,Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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onstrated bilateral hilar shadows and a relatively small
spleen. Under the diagnosis of septic shock, DIC, and
acute respiratory distress syndrome (ARDS), the patient
was admitted to the ICU. His Acute Physiology and
Chronic Health Evaluation (APACHE) II score was 26,
and his Sequential Organ Failure Assessment (SOFA)
score was 10. Streptococcus pneumoniae (serotype 22) was
detected in blood cultures and a diagnosis of purpura
fulminans caused by S. pneumoniae was made. Despite an
intensive care and antibiotic therapy, the purpura and
necrotic lesions spread over his face and extremities, and
eventually quadruple amputation was needed and actually
performed on day 7. Hemodialysis was unavoidable be-
cause of renal impairment, and multiple blood trans-
fusions were given due to prolonged pancytopenia.
Methylprednisolone 1 mg/kg/day was administered for
the treatment of ARDS, and the corticosteroid therapy
was gradually tapered to 5 mg/day of PSL, which was
the dosage prescribed before admission.
On day 71, vesicles accompanied by umbilical fossa
appeared diffusely and bilaterally on his face, trunk, and
extremities (Figure 1A, B). Vesicles were in various
stages, and a Tzanck preparation of the vesicles showed
multinucleated giant cells (Figure 1C). Systemic varicella
was suspected due to the appearance of these character-
istic vesicles, and the patient was isolated and treated
with intravenous acyclovir (reduced amount of 250 mg
every 24 h due to renal insufficiency). There were no(A)
(C)  
Figure 1 Photos of characteristic vesicles seen in Case 1. (A) The gross
of vesicles; blistering with central umbilical fossa. (C) A giant cell obtainedsymptoms or findings suggesting pneumonia, encephal-
itis, or hepatitis. Although his serum VZV-specific IgM
levels were not elevated, the IgG levels were found to be
elevated from 13.2 to more than 128 for 3 weeks (Vari-
cella-zoster IgG-EIA, Varicella-zoster IgM-EIA [SEIKEN],
DENKA SEIKEN CO., LTD. Tokyo, Japan.). Acyclovir was
administered for 7 days and the vesicles gradually formed
clusters that were completed after 11 days. His history
of VZV vaccination and VZV infection were unknown.
Recent contact with VZV patients was unlikely because of
his ongoing hospitalization in the ICU.
Case 2
A 75-year-old woman was admitted to our hospital
because of abdominal pain. Her past medical history
included coronary artery bypass grafting, aortic valve
replacement, atrial fibrillation, diabetes mellitus, obesity
(body mass index on admission was approximately 31),
and psoriasis vulgaris. She had taken oral steroids for
4 years for the treatment of psoriasis vulgaris and was
receiving 4 mg/day of PSL at the time of admission.
Contrast-enhanced CT revealed an entirely swollen,
poorly marginated pancreas, and she was diagnosed with
severe acute pancreatitis. The patient was initially admit-
ted to a general ward, however, respiratory failure wors-
ened, and she was admitted to the ICU and intubated on
the following day. Laboratory testing showed severe DIC,
and APACHE II and SOFA scores at the time of ICU
admission were 20 and 7, respectively.(B)
appearance of diffusely distributed vesicles. (B) The close appearance
from vesicles (Giemsa stain, 1,000 power field).
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consciousness was found to be worsened. Head CT re-
vealed multiple cerebral infarctions. Otherwise, her subse-
quent condition was relatively stable. However, on ICU
day 15, expiratory wheezing and vesicles appeared. By the
next day, the vesicles distributed bilaterally on her back
and buttocks that rapidly spread over her whole body. Sys-
temic varicella was diagnosed due to the characteristic
dermatological findings, and the patient was immediately
started on intravenous acyclovir (500 mg every 8 h) and
topical vidarabine. A liver disorder was detected 3 days
after vesicles appeared; transaminase levels were elevated
to maximums of 264 IU/L for aspartate aminotransferase
and 157 IU/L for alanine aminotransferase. Although the
patient's serum VZV-specific IgM levels were found to be
not elevated either as the patient in Case 1, the IgG levels
were elevated from 8.2 of one week before onset to 120.8
for two weeks. Under the diagnosis of VZV associated
pneumonia and hepatitis, she was treated with 7 days of
acyclovir. With treatment, respiratory wheezing and liver
disorder disappeared, clustering was completed, and then
patient left the ICU.
After that, she experienced a relapse of severe respira-
tory failure at the general ward. However, her family did
not authorize intubation because of patient’s unconscious
state at this time and eventually she died on hospital day
30. Although no autopsy was performed, chest radiog-
raphy revealed deteriorated bilateral pulmonary infiltra-
tions, and we clinically speculated that the patient died of
VZV pneumonia or ARDS.
A detail of the two cases is summarized in Table 1.
Discussion
Generally, critically ill patients have reduced cellular
immunocompetence [8]. The overproduction of anti-in-
flammatory cytokines due to a highly inflammatory state
causes immunosuppression, known as immunoparalysis
[11,12]. Corticosteroid therapy, which suppresses cellular-
mediated immunity, is frequently induced in various
situations, and its long-term use often let the patients
be immunocompetent state. Both patients presented
here were in immunocompromised states due to their
primary severe diseases and long period of corticoste-
roids administration. These conditions were considered
being related to the onset of systemic VZV infection.
Additionally, in Case 1, the relatively small spleen found
by CT (spleen dysfunction is associated with reduction of
humoral immunity [13]), the substantial blood transfu-
sions, and the quadruple amputation were considered the
other possible risk factors.
It was not clear whether these 2 cases were of dissemi-
nated zoster or varicella. The former is associated with
multiple vesicular skin lesions in a generalized distribu-
tion affecting a number of distinct dermatomes that donot cross the midline, and the latter involves diffusely
distributed several-staged vesicles. It is often difficult to
differentiate the one to the other. Although a report of
seemingly apparent varicella in an adult exists [14], atyp-
ical recurrent varicella without characteristic clustering
have been described in immunocompromised patients
[15,16]. We assumed that the presenting cases were vari-
cella, rather than zoster, because of the dermatological
appearance: diffuse and bilaterally distributed, but not
closely aggregated.
As shown, systemic VZV infection can be fatal. There-
fore, early detection and proper treatment is necessary.
The vesicles or blisters are characteristic dermatological
findings of VZV infection and can be the best indicator
for diagnosis. However, VZV infection can progress
without the appearance of typical vesicles, especially in
immunocompromised patients [15,16]. In addition, spe-
cific antibodies are not always elevated in such patients
[17,18]. Similarly, VZV pneumonia, the most frequent
complication in adults, develops insidiously, usually after
the onset of rash as seen in Case 2, and can progress to
acute respiratory failure or ARDS. For these reasons, the
early detection of systemic VZV infection is mandatory
but often difficult. Accordingly, VZV prophylaxis may be
required in some of immunosuppressed ICU patients to
prevent fatal VZV infection. In bone marrow transplant
recipients, the use of antiviral prophylaxis with low-dose
oral acyclovir (600 mg daily) or ganciclovir (5 mg/kg 3-
times weekly) is well established [17], but there is no
guideline concerning prophylaxis for VZV infection in
ICU. Acyclovir is also active against Human simplex
virus (HSV) types 1 and 2, and acyclovir resistant HSV
has been increasingly described as a problematic patho-
gen. Especially, the resistant organism has been isolated
from a variety of immunocompromised patients (preva-
lence around 5%), including bone marrow recipients
(prevalence reaching 30%), solid organ transplant recipi-
ents, and those with the acquired immunodeficiency
syndrome (AIDS) [19,20]. VZV resistance to acyclovir
has also been reported in patients with AIDS who had
been given chronic acyclovir therapy [21]. Moreover,
acyclovir has nephrotoxicity and drug interactions with
the other frequently used drugs. We should cautiously
determine the indicated patients if considering its use in
the ICU setting.
Vaccination, another method of preventing VZV infec-
tion, is not possible for critically ill patients in ICU
because it is the attenuated live vaccine and therefore
contraindicated for immunosuppressed patients.
For VZV-infected immunocompromised patients, early
high-dose acyclovir (e.g., 10 mg/kg 3-times daily) has
been recommended [4]. In adult patients who progress
to pneumonia or ARDS, corticosteroid therapy combined
with acyclovir has been shown to reduce the duration of
Table 1 A summary of the two cases
Case 1 Case 2
Sex Male Female
Age 69 75
Underlying disease MM, bone marrow transplantation and chemotherapy CABG, AVR, Af, DM, obesity, psoriasis vulgaris
Disease for ICU
admission
Streptococcus pneumonia-induced Purpura fulminans Severe acute pancreatitis
Complications after ICU
admission




History of VZV infection Unknown Unknown
Recent contact with
VZV
Not likely Not apparent
Steroid use before
admission
PSL, 5 mg/day PSL, 4 mg/day
Steroid use after
admission
mPSL, started with 1 mg/kg/day then tapered to PSL 5 mg/day PSL, 4 mg/day
APACHE II score 26 20









RCC, 78 units; FFP, 27 units; PC, 510 units None
EIA-IgM (cutoff; 0.8)
one week before onset 0.24 0.22
at the time of onset 0.15 0.15
after onset 0.52 (2 weeks) 0.47 (1 week)
EIA-IgG (cutoff; 2.0)
one week before onset 13.2 8.2
at the time of onset 34.5 102.5
after onset >128 (2 weeks after onset) 120.8 (1 week after onset)
Distribution of vesicles Vesicles with umbilical fossa appeared diffusely and bilaterally on face, trunk, and extremities
Time to cluster forming 11 days 7 days
Treatment, dose and
duration
250 mg of acyclovir every 24 h intravenously for 7 days and 5 g/
day of immunoglobulin for 3 days
500 mg of acyclovir every 8 h intravenously for 7 days
and vidarabine topically
Outcome Survived Died 14 days after the onset
Abbreviations: Af Atrial fibrillation, AKI acute kidney injury, APACHE II score Acute Physiology and Chronic Health Evaluation II score, ARDS Acute respiratory distress
syndrome, AVR Aortic valve replacement, CABG Coronary artery bypass grafting, DIC Disseminated Intravascular Coagulopathy, DM Diabetes mellitus, EIA Enzyme
Immunoassay, FFP Fresh frozen plasma, MM Multiple myeloma, mPSL methylprednisolone, PC Platelet concentration, PSL Prednisolone, RCC Red blood cell
concentration, SOFA score Sequential Organ Failure Assessment score, VAP Ventilator-associated pneumonia, VZV varicella-zoster virus.
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were treated with 7 days of acyclovir. The therapy success-
fully treated the patient in Case 1; however, it was failed in
Case 2. Although the relevance of the duration of acyclovir
therapy to outcome is unclear, the patients should have
been treated for longer period considering their impaired
immunological state.VZV is highly contagious; transmission occurs via
direct contact with lesions or via respiratory droplets.
Localized zoster is considered to transmit only by con-
tact, while the virus can be infected by air-borne trans-
mission in case of disseminated zoster. At present, there
are no reliable guidelines available concerning the hand-
ling of VZV patients in the ICU. However, since many
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http://www.virologyj.com/content/10/1/225ICU patients are in a state of immunosuppression, we
consider VZV patients should be isolated as soon as
possible, and appropriate antiviral treatment should be
initiated immediately to prevent the spread of the virus.
As for the two patients, although they were treated at
the same ICU, there was no chance of cross-contamin-
ation since their admission period was totally different
and not overlapped.
Conclusion
In summary, systemic VZV infection, although rare, can
cause serious and fatal complications in critically ill
patients in ICU. Early detection and proper treatment is
critical for minimizing mortality and controlling infec-
tion. However, the typical dermatological findings of
VZV infection and the elevation of specific antibodies
can be absent in immunosuppressed patients. Prophylac-
tic antiviral treatment, though not yet an established
approach, should be considered, particularly in markedly
immunosuppressed ICU patients.
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